Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access July 28, 2012

Plasma serotonin level in left-sided colonic diverticulosis: A pilot study

  • Katarzyna Neubauer EMAIL logo , Małgorzata Krzystek-Korpacka and Leszek Paradowski
From the journal Open Medicine


Neurotransmitters might participate in the development of diverticular disease. We measured fasting and postprandial serotonin levels in colonic diverticulosis patients and healthy volunteers. We demonstrated significantly lower maximal concentrations of serotonin in patients than the controls (respectively 109.8±61.4 and 251.3±44.1 ng/ml, p<0.001) as well as lower serotonin minimal values (respectively 38.4±21.8 and 124.6±41.4 ng/ml, p<0.001) and areas under time-course curves (respectively 288.8±139.8 and 739±167.4 ng/ml, p<0.001); significant difference between alternating pattern and normal bowel habit concerning fasting serotonin level, the hormone response to test meal (p=0.041) as well as minimal serotonin level (p=0.044). Bowel habit was also related to peak serotonin values following a test meal with 38.5 ng/ml in constipation, 139.5 ng/ml in diarrhea, 122.4 ng/ml in alternating pattern and 249 ng/ml in subjects with normal bowel habit (p=0.040) as well as AUC with 120.8 ng/ml in constipation, 416 ng/ml in diarrhea, 298 ng/ml in alternating pattern and 684 ng/ml in subjects with normal bowel habit (p=0.043). We demonstrated substantial differences in fasting serum serotonin levels as well as the hormone response to a test meal between colonic diverticulosis patients and healthy individuals, which seemed to be associated with abnormal bowel habits rather than presence of diverticula.

[1] Neubauer K., Dudkowiak R., Paradowski L., Leftsided diverticulosis of the large bowel as the second most common abnormality in colonoscopy — review of 425 cases of colonic diverticulosis, Adv. Clin. Exp. Med., 2010, 19, 513–518 Search in Google Scholar

[2] Nguyen G.C., Sam J., Anand N., Epidemiological trends and geographic variation in hospital admissions for diverticulitis in the United States, World J. Gastroenterol., 2011, 17, 1600–1605 in Google Scholar PubMed PubMed Central

[3] Jeyarajah S., Faiz O., Bottle A., Aylin P., Bjarnason I., Tekkis P.P., et al., Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions, Aliment. Pharmacol. Ther., 2009, 30, 1171–1182 in Google Scholar PubMed

[4] Jeyarajah S., Papagrigoriadis S., Review article: the pathogenesis of diverticular disease — current perspectives on motility and neurotransmitters, Aliment. Pharmacol. Ther., 2011, 33, 789–800 in Google Scholar PubMed

[5] Sikander A., Rana S.V., Prasad K.K., Role of serotonin in gastrointestinal motility and irritable bowel syndrome, Clin. Chim. Acta., 2009, 403, 47–55 in Google Scholar PubMed

[6] Banerjee S., Akbar N., Moorhead J., Rennie J.A., Leather A.J., Cooper D., Increased presence of serotonin-producing cells in colons with diverticular disease may indicate involvement in the pathophysiology of the condition, Int. J. Colorectal. Dis., 2007, 6, 643–649 in Google Scholar PubMed

[7] Costedio M.M., Coates M.D., Danielson A.B., Buttolph T.R. 3rd, Blaszyk H.J., Mawe G.M., et al., Serotonin signaling in diverticular disease, J. Gastrointest. Surg., 2008, 12, 1439–1445 in Google Scholar PubMed PubMed Central

[8] Spiller R., Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease, Neurogastroenterol. Motil., 2007, 19(Suppl. 2), 25–31 in Google Scholar PubMed

[9] Tan K.Y, Seow-Chowen F., Fiber and colorectal diseases: separating fact from fiction, World J. Gastroenterol., 2007, 13, 4161–4167 10.3748/wjg.v13.i31.4161Search in Google Scholar PubMed PubMed Central

[10] Spiller R.C.L., Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome, Curr. Opin. Pharmacol., 2011, 11, 68–74 in Google Scholar PubMed

[11] Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am. J. Gastroenterol., 2009, 104, 1831–1843 in Google Scholar PubMed

[12] Tursi A., Diverticular disease: a therapeutic overview, World J. Gastrointest. Pharmacol. Ther., 2010, 1, 27–35 in Google Scholar

[13] Dunlop S.P., Coleman N.S., Blackshow E., Perkins A.C., Singh G., Mardsen C.A., Spiller R.C., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 2005, 3, 349–357 in Google Scholar

[14] Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A., Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome, Gastroenterology, 2006, 130, 34–43 in Google Scholar PubMed

[15] Bearcroft C.P., Perrett D., Farthing M.J.G., Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study, Gut, 1998, 42, 42–46 in Google Scholar PubMed PubMed Central

Published Online: 2012-7-28
Published in Print: 2012-10-1

© 2012 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 2.6.2023 from
Scroll to top button